Interaction between lipoprotein (a) levels and body mass index in first incident acute myocardial infarction

Teng, Ruo-Ling; Wang, Heng; Sun, Bei-Chen; Cai, Dongge; He, Yao

doi:10.1186/s12872-020-01626-7

Cited by 9 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reports of a non-fully explained rise of Lp(a) with diet and exercise exist in literature (10). At the same time, it is found that an interaction with additive effect exists between BMI and Lp(a) in the risk for a first MI (11). In the current study, Lp(a) levels decreased significantly during the follow-up period, while a weak inverse relationship was observed between Lp(a) levels and BMI.…”

Section: Discussionsupporting

confidence: 52%

Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease

et al. 2022

View full text Add to dashboard Cite

A significant number of cardiovascular disease (CVD) patients, with the target lipid levels, as set by the guidelines, achieved, continue to remain at risk. In this setting, lipoprotein (Lp) a role in CVD prognosis is regaining interest. Although Lp(a) is related to the arteriosclerotic process, there is not currently an adequate amount of data for the inclusion of Lp(a) levels as a primary therapeutic target in the treatment of coronary artery disease (CAD) patients. In this framework, the current retrospective study aims to investigate the association of Lp(a) levels with the adverse cardiovascular (CV) events presented in a 10 year follow-up of CVD patients with dyslipidemia and its association with the major CV risk factors. A statistically significant reduction in Lp(a) levels was observed during the follow-up period (72.8±45.6 vs. 68.3±41.8 mg/dl; McNemar test; P<0.001). The vast majority of patients who suffered a new acute myocardial infarction during the follow up period had Lp(a) levels >30 mg/dl (24/28 patients, mean ± standard deviation Lp(a), 83.1±36.6 mg/dl, P=0.001). Kaplan-Meier survival analysis did not find statistically significant differences in a percutaneous coronary intervention (PCI) time occurrence during the follow-up period between patients with low (≤30 mg/dl) and high (>30 mg/dl) Lp(a) levels (log-rank P=0.305). On the other hand, when a second and third PCI conducted during the monitoring period were included in the Kaplan Meier analysis as events, the mean time for a PCI was significantly shorter (7.2%; P= 0.01) for patients with Lp(a) levels >30 mg/dl. In conclusion, the current study reported that patients with high Lp(a) values are more prone to the occurrence of new myocardial infarction, while the Lp(a) cut-off value of 30 mg/dl was linked in CVD patients to an earlier need for PCI, especially in the most vulnerable group of patients with more than one (recurrent) revascularizations.

show abstract

Section: Discussionsupporting

confidence: 52%

Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A cross-sectional study to assess the synergistic effect of Lp (a) and BMI in first incident myocardial infarction reported that elevated Lp (a) concentrations induce a high risk for initial acute myocardial infarction when BMI is elevated. 27 In a research study undertaken to determine the association between Lp (a) levels and high BMI, involving 69,988 individuals, highly elevated Lp (a) levels and high BMI were found to cause a higher risk of calcific aortic valve disease. 28 This study has some limitations.…”

Section: Discussionmentioning

confidence: 99%

Elevated lipoprotein (a) levels in hypertensive patients in southern part of Nigeria

Eguvbe,

Ologbo,

Ofili

et al. 2024

J Public Hlth Dev

View full text Add to dashboard Cite

Hypertension is linked with an increased risk of cardiovascular disease and is the leading modifiable risk factor for morbidity and mortality globally. Lipoprotein (a) is an independent risk factor for atherosclerotic cardiovascular disease. It has been suggested to contribute to increased risk for atherosclerosis in hypertensive patients. This study was to investigate the levels of Lp (a) in hypertensive patients and correlate them with other risk factors of cardiovascular disease. This was a hospital-based cross-sectional study conducted between October 2022 and December 2023 at the Delta State Central Hospital, Warri. The study involved 200 hypertensive patients and 100 healthy controls. The lipoprotein (a) levels in the hypertensives ranged from 5.2 – 89.0 mg/dl with a mean of 32.8 ± 16.6 mg/dl. The controls had a range of 1.1 – 63.2 mg/dl with a mean of 16.9 ± 13.9 mg/dl. The difference in mean Lp(a) levels was statistically significant (p <0.001). In the hypertensives, Lp(a) correlated positively with body weight (r = 0.522, p = 0.001), BMI (r = 0.553, p = 0.002) and waist circumference (r = 0.628, p = 0.001).Serum Lp (a) levels were significantly higher in the hypertensive patients than in the normotensive controls. There was a positive correlation between serum Lp (a) and BMI and waist circumference in the hypertensive group.

show abstract

“…[39] Two articles had reported that elevated Lp(a) levels may be associated with AMI in Chinese patients. [40,41] Lp(a) could also act as a biomarker to predict coronary collateral circulation or cardiovascular death in patients with AMI. [42,43] Additionally, Lp(a) interacts with LDL-C in first incident AMI in the Chinese Han population, so that the risk of initial AMI from exposure of elevated Lp(a) combined with elevated LDL-C is much greater than the sum of the risks of each alone.…”

Section: Atherosclerosismentioning

confidence: 99%

Lipoprotein(a) and Atherosclerotic Cardiovascular Diseases: Evidence from Chinese Population

2022

Cardiology Discovery

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is the leading cause of mortality worldwide. Multiple factors are involved in CVD, and emerging data indicate that lipoprotein(a) (Lp(a)) may be associated with atherosclerotic cardiovascular disease (ASCVD) independent of other traditional risk factors. Lp(a) has been identified as a novel therapeutic target. Previous studies on the influence of Lp(a) in CVD have mainly used in western populations. In this review, the association of plasma Lp(a) concentration with ASCVD was summarized, with regards to epidemiological, population-based observational, and pathological studies in Chinese populations. Lp(a) mutations and copy number variations in Chinese populations are also explored. Finally, the impact of plasma Lp(a) levels on patients with type 2 diabetes mellitus, cancer, and familial hypercholesterolemia are discussed.

show abstract

Interaction between lipoprotein (a) levels and body mass index in first incident acute myocardial infarction

Cited by 9 publications

References 26 publications

Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease

Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease

Elevated lipoprotein (a) levels in hypertensive patients in southern part of Nigeria

Lipoprotein(a) and Atherosclerotic Cardiovascular Diseases: Evidence from Chinese Population

Contact Info

Product

Resources

About